L
Laura Telep
Researcher at Cedars-Sinai Medical Center
Publications - 6
Citations - 2330
Laura Telep is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 1879 citations.
Papers
More filters
Journal ArticleDOI
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Jonathan Grein,Norio Ohmagari,Daniel Shin,George Diaz,Erika Asperges,Antonella Castagna,Torsten Feldt,Gary M. Green,Margaret L. Green,François-Xavier Lescure,Emanuele Nicastri,Rentaro Oda,Kikuo Yo,Eugenia Quiros-Roldan,Alex Studemeister,John Redinski,Seema Ahmed,Jorge Bernett,Daniel Chelliah,Danny Chen,Shingo Chihara,Stuart H. Cohen,Jennifer Cunningham,Antonella D’Arminio Monforte,Saad Ismail,Hideaki Kato,Giuseppe Lapadula,Erwan L’Her,Toshitaka Maeno,Sumit Majumder,Marco Massari,Marta Mora-Rillo,Yoshikazu Mutoh,Duc Nguyen,Ewa Verweij,Alexander Zoufaly,Anu Osinusi,Adam DeZure,Yang Zhao,Lijie Zhong,Anand Chokkalingam,Emon Elboudwarej,Laura Telep,Leighann Timbs,Ilana Henne,Scott Sellers,Huyen Cao,Susanna K. Tan,Lucinda Winterbourne,Polly Desai,Robertino Mera,Anuj Gaggar,Robert P. Myers,Diana M. Brainard,Richard Childs,Timothy Flanigan +55 more
TL;DR: In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients, and Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesavir therapy.
Journal ArticleDOI
Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States
W. Ray Kim,Laura Telep,Belinda Jump,Mei Lu,Heribert Ramroth,John F. Flaherty,Anuj Gaggar,Anand P. Chokkalingam,Stuart C. Gordon +8 more
TL;DR: This data indicates that the incidence of HCC among treatment‐naïve patients receiving TDF vs ETV in the United States is higher than that among patients receiving ETV.
Journal ArticleDOI
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment
Mark S. Sulkowski,Laura Telep,Massimo Colombo,François Durand,K. Rajender Reddy,Eric Lawitz,Marc Bourlière,Nelson Cheinquer,Stacey Scherbakovsky,Liyun Ni,Lindsey Force,Heribert Ramroth,Anuj Gaggar,Anand P. Chokkalingam,Meghan E. Sise +14 more
TL;DR: Sofosbuvir, a prodrug nucleoside inhibitor of hepatitis C virus, has a predominant circulating metabolite that is renally eliminated that is associated with chronic kidney disease progression.
Journal ArticleDOI
Identifying risk factors associated with hepatitis C virus infection in participants in the national health and nutrition examination survey using Super Learner
Journal ArticleDOI
Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir—A “knock‐out” is yet to be delivered—Authorsʼ reply
TL;DR: Kim et al. as discussed by the authors used Cox proportional hazard methods to measure the risk of HCC associated with different HBV treatment regimens in treatment-naïve populations and showed that for high-risk individuals, the NNT over 10 years is quite reasonable at <20, whereas it is much less so for low-risk subjects (column C).